Introduction Although many approaches have been tested to overcome the insulin
dependence caused by the pancreatic β-cells destruction observed in individuals affected …

Type 1 diabetes mellitus results from a T-cell mediated autoimmune destruction of the
pancreatic beta cells in genetically predisposed individuals. The knowledge of the …

Type 1 diabetes mellitus (T1DM) is a long‐term and chronic autoimmune disorder, in which
the immune system attacks the pancreatic β‐cells. Both adaptive and innate immune …

Type 1 diabetes (T1D) is an autoimmune disease driven by the activation of lymphocytes
against pancreatic β‐cells. Among β‐cell autoantigens, preproinsulin has been ascribed a …

Abstract Purpose of Review Type 1 diabetes (T1D) is an autoimmune disease marked by β-
cell destruction. Immunotherapies for T1D have been investigated since the 1980s and have …

Type 1 diabetes is characterized by recognition of one or more β-cell proteins by the
immune system. The list of target antigens in this disease is ever increasing and it is …

It has been more than 30 years since the initial trials of Cyclosporin A to treat patients with
new onset Type 1 diabetes (T1D). Since that time, there have been insights into genetic …

Type 1 diabetes (T1D) is characterized by the unresolved autoimmune inflammation and
islet β cell destruction. The islet resident antigen-presenting cells (APCs) including dendritic …

Background Preservation of beta cell function is a central goal in type 1 diabetes (type 1 DM)
immune intervention. The characterization of individuals with recovery from established type …

Our understanding of the immunopathological features of type 1 diabetes (T1D) has greatly
improved over the past two decades and has shed light on disease heterogeneity dictated …